Endocrinology and Metabolism10.3803/enm.2020.35.2.3672020352367-376Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying TreatmentsYe Seul Yang, Seo Young Lee, Jung-Sun Kim, Kyung Mook Choi, Kang Wook Lee, Sang-Chol Lee, Jung Rae Cho, Seung-Jin Oh, Ji-Hyun Kim, Sung Hee Choi,,
Atherosclerosis10.1016/j.atherosclerosis.2014.05.86820142352e289Lipid target achievement among patients according to ESC/EAS and ACC/AHA guidelines in a lipid clinicH. Milionis, F. Barkas, E. Liberopoulos, M. Kostapanos, E. Klouras, M. Elisaf,
Atherosclerosis10.1016/j.atherosclerosis.2011.09.0422012220142-44News from the literature: Focus on joint ESC/EAS dyslipidemia guidelinesJane Stock,
Atherosclerosis10.1016/j.atherosclerosis.2021.05.0132021EAS Task Force gives practical guidance for combination lipid-modifying therapy in high- and very-high-risk patientsJane K. Stock,
International Journal of Cardiology10.1016/j.ijcard.2020.05.0552020316229-235Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registryLeonardo De Luca, Marcello Arca, Pier Luigi Temporelli, Jennifer Meessen, Carmine Riccio, Paolo Bonomo, Angela Rita Colavita, Domenico Gabrielli, Michele Massimo Gulizia, Furio Colivicchi,
Journal of Lipid and Atherosclerosis10.12997/jla.2015.4.1.61201541612015 Korean Guidelines for Management of Dyslipidemia,,
European Heart Journal10.1093/eurheartj/ehz826201941444255-4255Corrigendum to: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk,
Revista Española de Cardiología (English Edition)10.1016/j.rec.2020.04.00620207354032019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk,
European Heart Journal10.1093/ehjci/ehaa946.3003202041Supplement_2What is the potential cardiovascular risk reduction associated with achieving LDL-C levels recommended in the ESC/EAS guidelines for very high-risk patients? Data from 18 European countriesK.K Ray, S Bray, A.L Catapano, N Poulter, G Villa,
Journal of Pharmaceutical Health Services Research10.1111/jphs.123712020114423-427Critical Appraisal of the Clinical Practice Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk: European Society of Cardiology (ESC) and European Atherosclerosis Society (ESC/EAS) 2019 GuidelinesEman N Alhmoud, Raja Barazi, Amr Fahmi, Abdullah Abdu, Alya Higazy, Maguy ElHajj,,,,